ConductScience.org, home

Paper28656259

Anti-angiogenesis target therapy for advanced osteosarcoma (Review).

Xie L and 2 others. Oncol Rep, 2017. Cited by 94 papers, by iCite.

Cite this record

ConductScience Library. Anti-angiogenesis target therapy for advanced osteosarcoma (Review). Papers, record 28656259. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28656259

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-angiogenesis target therapy for advanced osteosarcoma (Review).
PubMed
Journal
Oncol Rep
PubMed
Year
2017
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
94
iCite
Relative citation ratio, by iCite
3.89
iCite
Revised in PubMed
2018-11-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xie LLu
2Ji TTao
3Guo WWei

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lung NeoplasmsMajor topic
Neovascularization, PathologicMajor topic
OsteosarcomaMajor topic
Disease-Free Survival
Gene Expression Regulation, Neoplastic
Humans
Neoplasm Metastasis
Neoplasm Staging
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1

Source PubMed

Download CSV of topics

References119

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121527590A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.Ann Oncol2012https://conductscience.org/library/papers/21527590PubMed
216809160Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients.Cancer Invest2006https://conductscience.org/library/papers/16809160PubMed
316226705Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.Cancer Cell2005https://conductscience.org/library/papers/16226705PubMed
415479481Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.Clin Colorectal Cancer2004https://conductscience.org/library/papers/15479481PubMed
523589053A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.Tumour Biol2013https://conductscience.org/library/papers/23589053PubMed
622669161Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.Br J Cancer2012https://conductscience.org/library/papers/22669161PubMed
721495021Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma.Cancer2011https://conductscience.org/library/papers/21495021PubMed
825126591Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis.Oncoscience2014https://conductscience.org/library/papers/25126591PubMed
926330427New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype.Clin Cancer Res2015https://conductscience.org/library/papers/26330427PubMed
1020003259
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Mol Cancer2009https://conductscience.org/library/papers/20003259PubMed
1126440568Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors.Nucl Med Commun2016https://conductscience.org/library/papers/26440568PubMed
1220842228Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.J Cancer2010https://conductscience.org/library/papers/20842228PubMed
1312177445VEGF-Trap: a VEGF blocker with potent antitumor effects.Proc Natl Acad Sci U S A2002https://conductscience.org/library/papers/12177445PubMed
1419261927High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.Radiology2009https://conductscience.org/library/papers/19261927PubMed
1524613529Anti-angiogenic therapy, a new player in the field of sarcoma treatment.Crit Rev Oncol Hematol2014https://conductscience.org/library/papers/24613529PubMed
1626291057Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.Br J Cancer2015https://conductscience.org/library/papers/26291057PubMed
1725145405Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer.Acta Med Okayama2014https://conductscience.org/library/papers/25145405PubMed
1817942672Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17942672PubMed
1915985268Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells.Life Sci2005https://conductscience.org/library/papers/15985268PubMed
2011357143Oncogenic kinase signalling.Nature2001https://conductscience.org/library/papers/11357143PubMed

See all 119 referencesDownload CSV of references

Cited by62

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.

PMIDTitleJournalYearIn PapersSource
41553639Aging reshapes the osteosarcoma ecosystem through immune dysfunction and tumor cell reprogramming.Cell Oncol (Dordr)2026https://conductscience.org/library/papers/41553639PubMed
41395622Efficacy and safety of anlotinib for the treatment of advanced bone and soft tissue sarcomas: a systematic review and meta-analysis.Front Oncol2025https://conductscience.org/library/papers/41395622PubMed
41301872Biomimetic Porous Coatings on a Biocompatible Ti-15Mo Alloy as a Platform for Local Delivery of Anticancer Drugs to Patient Tissues.Biomedicines2025https://conductscience.org/library/papers/41301872PubMed
40989695Identification of MAEA protein as a potential target for chemoresistance in osteosarcoma using bioinformatics and proteomic analysis.Front Oncol2025https://conductscience.org/library/papers/40989695PubMed
40676851Pathobiology and Molecular Pathways Implicated in Osteosarcoma Lung Metastasis: A Scoping Review.Technol Cancer Res Treat2025https://conductscience.org/library/papers/40676851PubMed
39769419Whole-Exome Analysis and Osteosarcoma: A Game Still Open.Int J Mol Sci2024https://conductscience.org/library/papers/39769419PubMed
39252946Targeted anti-angiogenesis therapy for advanced osteosarcoma.Front Oncol2024https://conductscience.org/library/papers/39252946PubMed
38948019Exploring the effects of taurolidine on tumor weight and microvessel density in a murine model of osteosarcoma.Oncol Res2024https://conductscience.org/library/papers/38948019PubMed
38835052System analysis based on Anoikis-related genes identifies MAPK1 as a novel therapy target for osteosarcoma with neoadjuvant chemotherapy.BMC Musculoskelet Disord2024https://conductscience.org/library/papers/38835052PubMed
37404767Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma.Front Oncol2023https://conductscience.org/library/papers/37404767PubMed
37377920A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma.Front Oncol2023https://conductscience.org/library/papers/37377920PubMed
37300290SP-8356 (A Verbenone Derivative) Inhibits Proliferation, Suppresses Cell Migration and Invasion and Decreases Tumor Growth of Osteosarcoma: Role of PGC-1α/TFAM and AMPK-Activation.Cell J2023https://conductscience.org/library/papers/37300290PubMed
36983138Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients.J Clin Med2023https://conductscience.org/library/papers/36983138PubMed
36944946Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.J Nanobiotechnology2023https://conductscience.org/library/papers/36944946PubMed
36765658Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas.Cancers (Basel)2023https://conductscience.org/library/papers/36765658PubMed
36759884Abnormal signal pathways and tumor heterogeneity in osteosarcoma.J Transl Med2023https://conductscience.org/library/papers/36759884PubMed
36632464Ebastine exerts antitumor activity and induces autophagy by activating AMPK/ULK1 signaling in an IPMK-dependent manner in osteosarcoma.Int J Biol Sci2023https://conductscience.org/library/papers/36632464PubMed
36618348Comprehensive analysis of a glycolysis and cholesterol synthesis-related genes signature for predicting prognosis and immune landscape in osteosarcoma.Front Immunol2022https://conductscience.org/library/papers/36618348PubMed
36177059The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis.Biomed Res Int2022https://conductscience.org/library/papers/36177059PubMed
36176756An overview of resistance to chemotherapy in osteosarcoma and future perspectives.Cancer Drug Resist2022https://conductscience.org/library/papers/36176756PubMed

See all 62 cited byDownload CSV of cited by

Genes40

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABL125PubTator's text mininghttps://conductscience.org/library/genes/25NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
COL18A180781PubTator's text mininghttps://conductscience.org/library/genes/80781NCBI Gene
CSF1R1436PubTator's text mininghttps://conductscience.org/library/genes/1436NCBI Gene
CSF21437PubTator's text mininghttps://conductscience.org/library/genes/1437NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EIF4E1977PubTator's text mininghttps://conductscience.org/library/genes/1977NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
FGF12246PubTator's text mininghttps://conductscience.org/library/genes/2246NCBI Gene
FGF22247PubTator's text mininghttps://conductscience.org/library/genes/2247NCBI Gene
FGFR12260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
FKBP1AP42285PubTator's text mininghttps://conductscience.org/library/genes/2285NCBI Gene
FLT12321PubTator's text mininghttps://conductscience.org/library/genes/2321NCBI Gene
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
FLT42324PubTator's text mininghttps://conductscience.org/library/genes/2324NCBI Gene
HGF3082PubTator's text mininghttps://conductscience.org/library/genes/3082NCBI Gene
IFNA13439PubTator's text mininghttps://conductscience.org/library/genes/3439NCBI Gene
IGF1R3480PubTator's text mininghttps://conductscience.org/library/genes/3480NCBI Gene
KDR3791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene

See all 40 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28656259

GET https://conductscience.org/api/papers/v1/28656259/references?page=2